Salvador Gámez Casado

Dr. Salvador Gámez Casado

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2024 in Respirology Case Reports
Verified
Journal Article
Open access
SCSalvador Gámez Casado
Salvador Gámez Casado
JFJavier David Benitez Fuentes
Javier David Benitez Fuentes
BRBeatriz Álvarez Rodríguez
Beatriz Álvarez Rodríguez
GLGema García Ledo
Gema García Ledo
Oncogene‐negative, PDL1‐negative metastatic non‐small cell lung cancer (NSCLC) presents significant treatment challenges due to its complexity and resistance to conventional therapies. The case report presented addresses a 55‐year‐old male patient with oncogene‐negative, PDL1‐negative stage IV lung adenocarcinoma, showcasing an exceptional complete metabolic response to a multimodality treatment combining double immune checkpoint inhibition (ICI) and chemotherapy, followed by salvage stereotactic body radiotherapy (SBRT). The patient underwent a treatment regimen incorporating two cycles of carboplatin, pemetrexed, nivolumab, and ipilimumab followed by nivolumab, and ipilimumab maintenance. After a partial response, SBRT was applied to persistent lesions, achieving a complete metabolic response. This case highlights the potential of combining dual ICI with chemotherapy and SBRT in treating oncogene‐negative, PDL1‐negative NSCLC underscoring the importance of multimodality treatment strategies.

7 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SCSalvador Gámez Casado
Salvador Gámez Casado
LRLourdes Rodríguez-Pérez
Lourdes Rodríguez-Pérez
CBCristina Bandera-López
Cristina Bandera-López
AMAndrés Mesas
Andrés Mesas
ACAlicia Campini-Bermejo
Alicia Campini-Bermejo
JBJose M Baena-Canada
Jose M Baena-Canada
Background. Implementing mammogram screening means that clinicians are seeing many breast cancers that will never develop metastases. The purpose of this study was to identify subgroups of breast cancer patients who did not present events related to long-term breast cancer mortality, taking into account diagnosis at breast screening, absence of palpability and axillary involvement, and genomic analysis with PAM50. Patients and Methods. To identify them, a retrospective observational study was carried out selecting patients without any palpable tumor and without axillary involvement, and a genomic analysis was performed with PAM50. Results. The probability of distant metastasis-free interval (DMFI) of 337 patients was 0.92 (95% CI, 0.90–0.93) at 20 years and 0.96 (95% CI, 0.92–1.00) in 95 patients (28%) with available PAM50 tests. In 22 (23.15%) luminal A tumors and in 9 (9.47%) luminal B tumors smaller than 1 cm, and in HER2 and basal type tumors, there were no metastatic events (20-year DMFI of 1.00). Conclusion. Patients with nonpalpable breast cancer found at screening with negative nodes are at very low risk. It is possible to identify subgroups without metastatic events by determining the intrinsic subtype and tumor size less than 1 cm. Therefore, de-escalation of treatment should be considered.

5 February 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
SCSalvador Gámez Casado
Salvador Gámez Casado
LRLourdes Rodríguez-Pérez
Lourdes Rodríguez-Pérez
CBCristina Bandera-López
Cristina Bandera-López
AMAndrés Mesas
Andrés Mesas
ABAlicia Campini Bermejo
Alicia Campini Bermejo
JBJose M Baena-Canada
Jose M Baena-Canada
Background. Implementing mammogram screening means that clinicians are seeing many breast cancers that will never develop metastases. The purpose of this study was to identify subgroups of breast cancer patients who did not present events related to long-term breast cancer mortality, taking into account diagnosis at breast screening, absence of palpability and axillary involvement, and genomic analysis with PAM50. Patients and Methods. To identify them, a retrospective observational study was carried out selecting patients without palpable tumour, without axillary involvement, and a genomic analysis was performed with PAM50. Results. The probability of distant metastasis-free interval (DMFI) of 337 patients was 0.92 (95% CI, 0.90-0.93) at 20 years and 0.96 (95% CI, 0.92-1.00) in 95 patients (28%) with available PAM50 tests. In 22 (23.15%) luminal A tumours and in 9 (9.47%) luminal B tumours smaller than 1 cm and in HER2 and basal type tumours there were no metastatic events (20-year DMFI of 1.00). Conclusion. Patients with nonpalpable breast cancer found at screening with negative nodes are at very low risk. It is possible to identify subgroups without metastatic events by determining the intrinsic subtype and tumour size less than 1 cm. De-escalation of treatment should be considered.